Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer
N Reed, H Glen, G Gerrard, J Good, M Lei, AR Lyon… - Clinical Oncology, 2020 - Elsevier
Aims Lenvatinib is an oral multi-kinase inhibitor approved for the treatment of adults with
progressive, locally advanced or metastatic, differentiated thyroid carcinoma refractory to …
progressive, locally advanced or metastatic, differentiated thyroid carcinoma refractory to …
Drug safety evaluation of lenvatinib for thyroid cancer
J Krajewska, A Kukulska, B Jarzab - Expert Opinion on Drug Safety, 2015 - Taylor & Francis
Introduction: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor of VEGFR1, 2, 3, 4,
FGFR1, 2, 3, 4, PDGFR-α as well as RET and KIT signaling network. Its activity against …
FGFR1, 2, 3, 4, PDGFR-α as well as RET and KIT signaling network. Its activity against …
[HTML][HTML] Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
ME Cabanillas, S Takahashi - Seminars in Oncology, 2019 - Elsevier
Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …
[HTML][HTML] Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes
RI Haddad, M Schlumberger, LJ Wirth, EJ Sherman… - Endocrine, 2017 - Springer
Purpose In the study of (E7080) lenvatinib in differentiated cancer of the thyroid, most
patients experienced an adverse event. In this report, we examine common lenvatinib …
patients experienced an adverse event. In this report, we examine common lenvatinib …
Lenvatinib long-term responses in refractory thyroid cancer: our mono-institutional real-life experience with the multidisciplinary approach and review of literature
N Denaro, A Latina, F Cesario, F Bramardi, L Corrado… - Oncology, 2019 - karger.com
Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved
in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and …
in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and …
Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application
RM Paragliola, A Corsello, V Del Gatto… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …
Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
L Lorusso, K Newbold - Future Oncology, 2015 - Taylor & Francis
ABSTRACT Lenvatinib mesylate (E7080; 4-[3-chloro-4-(N′-cyclopropylureido) phenoxy] 7-
methoxyquinoline-6-carboxamide mesylate) is an oral molecule that inhibits multiple …
methoxyquinoline-6-carboxamide mesylate) is an oral molecule that inhibits multiple …
Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects
S Hamidi, A Boucher, B Lemieux… - Journal of the …, 2022 - academic.oup.com
Context The SELECT trial led to the approval of lenvatinib for the treatment of advanced
radioiodine-refractory differentiated thyroid carcinomas (DTCs) but also revealed an …
radioiodine-refractory differentiated thyroid carcinomas (DTCs) but also revealed an …
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer
S Takahashi, N Kiyota, T Yamazaki, N Chayahara… - Future …, 2019 - Taylor & Francis
Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.
Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory …
Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory …
Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers
S Jasim, NM Iniguez-Ariza, CR Hilger… - Endocrine Practice, 2017 - Elsevier
Objective: Lenvatinib is approved for use in advanced radioactive iodine-resistant
differentiated thyroid cancers (RAIR-DTCs). Its efficacy is indisputable, but toxicities are …
differentiated thyroid cancers (RAIR-DTCs). Its efficacy is indisputable, but toxicities are …
相关搜索
- thyroid cancer adverse events
- lenvatinib for thyroid cancer
- thyroid cancer expert consensus
- differentiated thyroid cancers
- thyroid cancer practical management
- patients with advanced thyroid cancer
- refractory thyroid cancer
- thyroid cancer safety efficacy
- thyroid cancer toxicities in patients
- thyroid cancer side effects
- treatment with lenvatinib adverse events
- expert consensus adverse events
- treatment with lenvatinib expert consensus
- lenvatinib therapy adverse events
- lenvatinib therapy safety efficacy
- lenvatinib therapy side effects